Literature DB >> 9721878

The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers.

L C Chen1, S Manjeshwar, Y Lu, D Moore, B M Ljung, W L Kuo, S H Dairkee, M Wernick, C Collins, H S Smith.   

Abstract

Amplification is a key mechanism whereby a cancer cell increases the message level of genes that confer a selective advantage when they are overexpressed. In breast cancer, there are many chromosome regions present in multiple copies relative to overall DNA copy number (amplicons), and their target genes are unknown. Using differential display, we have cloned and sequenced the full coding region of a candidate amplicon target gene located on chromosome 13. This candidate is the human homologue of the Caenorhabditis elegans cul-4 gene, cul-4A, a member of the novel cullin gene family, which is involved in cell cycle control of C. elegans. cul-4A was amplified and overexpressed in 3 of 14 breast cancer cell lines analyzed, and it was overexpressed in 8 additional cell lines in which it was not amplified. The latter observation, indicating that its overexpression can occur by mechanisms other than gene amplification, suggests that cul-4A plays a key role in carcinogenesis. Moreover, cul-4A was found to be amplified in 17 of 105 (16%) cases of untreated primary breast cancers, and 14 of 30 cases analyzed (47%) were shown by RNA in situ hybridization to overexpress cul-4A. These results suggest that up-regulation of cul-4A may play an important role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721878

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  85 in total

1.  CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein.

Authors:  Yue Zhang; Giovanni Morrone; Jianxuan Zhang; Xiaoai Chen; Xiaoling Lu; Liang Ma; Malcolm Moore; Pengbo Zhou
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

Review 2.  Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Authors:  Tomoaki Tanaka; Tatsuya Nakatani; Tetsu Kamitani
Journal:  Mol Oncol       Date:  2012-01-21       Impact factor: 6.603

Review 3.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

4.  Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis.

Authors:  Binghui Li; Nan Jia; Reuben Kapur; Kristin T Chun
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

5.  X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression.

Authors:  Tadashi Nakagawa; Yue Xiong
Journal:  Mol Cell       Date:  2011-08-05       Impact factor: 17.970

6.  REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase.

Authors:  Samiksha Katiyar; Enbo Liu; Christine A Knutzen; Elizabeth S Lang; Christian R Lombardo; Sabita Sankar; Julia I Toth; Matthew D Petroski; Ze'ev Ronai; Gary G Chiang
Journal:  EMBO Rep       Date:  2009-06-26       Impact factor: 8.807

Review 7.  Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases.

Authors:  Jeffrey Hannah; Pengbo Zhou
Journal:  DNA Repair (Amst)       Date:  2009-02-23

8.  DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases.

Authors:  Yizhou Joseph He; Chad M McCall; Jian Hu; Yaxue Zeng; Yue Xiong
Journal:  Genes Dev       Date:  2006-11-01       Impact factor: 11.361

Review 9.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

10.  Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Authors:  Dongping Wei; Meredith A Morgan; Yi Sun
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.